Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response

Aliment Pharmacol Ther. 2019 Jan;49(2):236-238. doi: 10.1111/apt.15049.

Authors

Christophe Corpechot^{1

2}, Olivier Chazouillères^{1

2}, Sara Lemoinne^{1

2}, Alexandra Rousseau³

Affiliations

¹ Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
² INSERM UMR_S938, Sorbonne University, Paris, France.
³ Clinical Research Platform of East of Paris, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.

PMID: 30589964
DOI: 10.1111/apt.15049

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Bezafibrate
Cholangitis*
Fenofibrate*
Humans
Liver Cirrhosis, Biliary*
Liver Transplantation*
Ursodeoxycholic Acid

Substances

Ursodeoxycholic Acid
Fenofibrate
Bezafibrate

Associated data

ClinicalTrials.gov/NCT01654731

Grants and funding